Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimebon in mild-to-moderate Alzheimer's disease (CONNECTION)
NCT00675623Phase 3Completed
- Sponsor
- Medivation
- Start
- May 2008
- Primary completion
- Dec 2009
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of latrepirdine in Alzheimer's disease (AD), sponsored by Medivation. Primary endpoint: Alzheimer's Disease Assessment Scale-cognitive subscale at 26 weeks. Started May 2008; status: completed.
02
Drugs
latrepirdine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00675623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00675623.